- Home
- NPT vs SERA Comparison
NPT vs SERA Comparison
Compare NPT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | SERA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9M | 134.3M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NPT | SERA |
|---|---|---|
| Price | $6.09 | $3.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 71.7K | 67.5K |
| Earning Date | 02-23-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $797,148,640.00 | $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.51 | 1.06 |
| 52 Week Low | $3.14 | $1.37 |
| 52 Week High | $9.18 | $6.92 |
Technical Indicators
Market Signals| Indicator | NPT | SERA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.90 |
| Support Level | N/A | $3.30 |
| Resistance Level | N/A | $3.69 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 68.69 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.